Quanterix (QTRX) Stock Price, News & Analysis

Company Overview

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Key Stats

• Today's Range: $5.26 to $5.65
• 50-Day Range: $4.81 to $7.65
• 52-Week Range: $4.67 to $19.18
• Volume: 348,159 shs
• Average Volume: 548,710 shs
• Market Capitalization: $204.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.20
• Consensus Rating: Moderate Buy

Quanterix Stock Analysis - MarketRank™

Quanterix scored higher than 44% of companies evaluated by MarketBeat, and ranked 640th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Quanterix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Quanterix has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Quanterix are expected to decrease in the coming year, from ($0.98) to ($1.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quanterix is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quanterix is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quanterix has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.45% of the float of Quanterix has been sold short.

Short Interest Ratio / Days to Cover

Quanterix has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quanterix has recently decreased by 3.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quanterix does not currently pay a dividend.

Dividend Growth

Quanterix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.45% of the float of Quanterix has been sold short.

Short Interest Ratio / Days to Cover

Quanterix has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quanterix has recently decreased by 3.52%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.88

News Sentiment

Quanterix has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Quanterix this week, compared to 5 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quanterix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Quanterix is held by insiders.

Percentage Held by Institutions

86.48% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QTRX Stock Analysis - Frequently Asked Questions

How have QTRX shares performed this year?

Quanterix's stock was trading at $10.63 at the beginning of the year. Since then, QTRX stock has decreased by 50.3% and is now trading at $5.28.
View the best growth stocks for 2025 here.

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) posted its earnings results on Monday, March, 17th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.03. The firm earned $35.16 million during the quarter, compared to the consensus estimate of $34.93 million. Quanterix had a negative net margin of 30.12% and a negative trailing twelve-month return on equity of 11.74%.
Read the conference call transcript.

When did Quanterix IPO?

Quanterix (QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Top institutional shareholders of Quanterix include Easterly Investment Partners LLC (3.42%), Baillie Gifford & Co. (1.55%), Trium Capital LLP (1.44%) and Envestnet Asset Management Inc. (1.29%). Insiders that own company stock include David R Walt, E Kevin Hrusovsky, Masoud Toloue, Michael A Doyle, John J Fry and William P Donnelly.
View institutional ownership trends.

How do I buy shares of Quanterix?

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quanterix investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 5/11/2025
• Next Earnings (Confirmed): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:QTRX
• CIK: 1503274
• Web: www.quanterix.com
• Phone: (617) 301-9400
• Fax: N/A
• Employees: 460
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.20
• High Stock Price Target: $24.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +206.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-28,350,000.00
• Net Margins: -30.12%
• Pretax Margin: -26.26%
• Return on Equity: -11.74%
• Return on Assets: -9.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.07
• Quick Ratio: 9.16

Sales & Book Value

• Annual Sales: $135.44 million
• Price / Sales: 1.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.25 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 38,789,000
• Free Float: 35,866,000
• Market Cap: $204.81 million
• Optionable: Optionable
• Beta: 1.12